Introduction
LOURIE, Circuit Judge
In this patent infringement case, Iolab Corporation appeals from the decision of the United States District Court for the Southern District of Florida awarding the patentee, Dr. Jaswant S. Pannu, damages and enjoining Iolab from further infringement. Because the district court erred in granting Pannu’s motion for judgment as a matter of law (JMOL) that Iolab could not invalidate the patent, U.S. Reissue Patent 32,525, on the ground of improper inventorship, we reverse the grant of JMOL, vacate the judgment of infringement, and remand.
Iolab also appeals and Pannu cross-appeals from the denial of their respective renewed motions for JMOL following the jury verdict that two of the four accused devices infringe, while the other two accused devices do not. Iolab asserts that the court’s claim construction was erroneous; Pannu asserts that the findings of non-infringement were tainted by a variety of prejudicial errors. Because the district court did not err in construing the claims, the jury’s findings were supported by substantial evidence, and the court did not abuse its discretion in its procedural decisions, we do not disturb the court’s denial of the parties’ post-trial motions.
In this case; the appellate court held that this court “erred by not sending the inventorship issue to the jury.” Dr. Pannu’s concession that he and Dr. William Link (“Dr.Link”) discussed the invention and that Dr. Link contributed the idea of one-piece construction for the intraocular lens was held sufficient evidence for a reasonable jury to find that Dr. Link (a nonparty) was an actual inventor. Other factors regarding the significance of Dr. Link’s contribution and the timeliness of the claim were not considered obviously because they had not been articulated by this court as grounds for deciding the inventorship issue as a matter of law.
Background of the Case
The case centers around a patent dispute regarding an accommodating intraocular lens (IOL), a medical device developed by Dr. Jaswant S. Pannu to replace the natural lens of the eye following cataract surgery. This innovative lens design sought to address critical issues with traditional IOLs, particularly by reducing tissue damage during implantation and improving the eye’s ability to focus on both near and distant objects.
Dr. Pannu initially filed a patent application for this lens in 1980. Later, he collaborated with Dr. William Link, an ophthalmic scientist from Heyer-Schulte, who proposed a significant improvement to the design, the lens should be constructed as a single-piece unit. This modification was pivotal because it not only simplified the manufacturing process but also enhanced the overall performance of the lens.
Incorporating Dr. Link’s suggestion, Dr. Pannu filed a continuation-in-part patent application in 1981, which eventually led to the issuance of U.S. Patent No. 4,435,855. This patent was later reissued as U.S. Reissue Patent No. 32,525 (referred to as the ‘525 patent). However, a dispute arose when Dr. Pannu accused Iolab Corporation of infringing on this patent. In its defense, Iolab argued that the patent was invalid because Dr. Link had not been named as a co-inventor, despite his significant contribution to the invention.
The legal question was whether this contribution was substantial enough to qualify Dr. Link as a co-inventor under 35 U.S.C. § 102(f) and whether the error of omitting him could be corrected under 35 U.S.C. § 256.
Legal Issues
1. Inventorship under 35 U.S.C. § 102(f):
Was the patent invalid because Dr. Link, who contributed significantly to the invention, was not named as a co-inventor?
2. Correction under 35 U.S.C. § 256:
Could the omission of Dr. Link’s name be corrected under § 256, which permits adding or removing inventors as long as the error was not made with deceptive intent?
3. Joint Inventorship:
Did Dr. Link’s contribution of the single-piece design qualify as a significant inventive input sufficient to make him a co-inventor?
1. Inventorship under 35 U.S.C. § 102(f):
Was the patent invalid because Dr. Link, who contributed significantly to the invention, was not named as a co-inventor?
Under 35 U.S.C. § 102(f), inventorship is a fundamental requirement for patent validity. The statute mandates that a patent must accurately list the true inventors-those who contributed to the conception of the invention. If an inventor is omitted or incorrectly named, the patent could be rendered invalid.
In this case, Iolab argued that Dr. Link’s omission as a co-inventor invalidated the patent, as he made a significant contribution to the invention of the intraocular lens. Dr. Link’s idea for a single-piece design was deemed essential to the invention, and the failure to include him as an inventor raised the issue of improper inventorship. The Court of Appeals agreed that there was sufficient evidence suggesting that Dr. Link’s contribution could have been substantial enough to require his inclusion as a co-inventor.
However, the district court prematurely granted Judgment as a Matter of Law (JMOL) in favor of Dr. Pannu, ruling that Dr. Link was not a co-inventor. The Court of Appeals found that this decision was made too early and vacated the judgment, remanding the case for the jury to determine whether Dr. Link should have been listed as a co-inventor. As a result, the question of whether the patent was invalid due to improper inventorship remained unresolved at the time of the appeal.
2. Correction under 35 U.S.C. § 256
Could the omission of Dr. Link’s name be corrected under § 256, which permits adding or removing inventors as long as the error was not made with deceptive intent?
Yes, the omission of Dr. Link’s name could potentially be corrected under 35 U.S.C. § 256. This section allows for the correction of inventorship errors, specifically in cases of misjoinder or non-joinder, as long as the error was made without deceptive intent.
The Court of Appeals emphasized that inventorship errors do not automatically render a patent invalid if they can be corrected under section 256. If it is determined that Dr. Link should have been included as a co-inventor, the patent could be amended under section 256, and the omission would not invalidate the patent. The Court of Appeals found that the district court had not given Dr. Pannu the opportunity to invoke section 256 and correct the patent after determining that Dr. Link should be added. The case was thus sent back to the lower court, where Dr. Pannu would have the opportunity to correct the inventorship error if Dr. Link’s contribution was recognized by the jury.
3. Joint Inventorship
Did Dr. Link’s contribution of the single-piece design qualify as a significant inventive input sufficient to make him a co-inventor?
Yes, Dr. Link’s contribution of the single-piece design for the intraocular lens was deemed a significant inventive input. Under U.S. patent law, joint inventorship requires that each person contributed substantially to the conception of the invention. Conception refers to the formation of a complete and definite idea that is specific enough for someone skilled in the field to reduce it to practice.
In this case, the Court of Appeals found that Dr. Link’s suggestion of the single-piece design was not merely a trivial or routine suggestion. The Court concluded that Dr. Link’s contribution addressed a critical problem in lens design and played a key role in the final form of the invention. The single-piece design was incorporated into the patent claims, which directly impacted the functionality and manufacturability of the lens.
Thus, Dr. Link’s contribution was deemed substantial enough to qualify him as a co-inventor. The Court of Appeals ruled that the matter should be determined by the jury, as there was enough evidence to suggest that Dr. Link should have been named as a co-inventor, and the jury should decide whether his contribution met the threshold for joint inventorship.
Court Analysis
1. How does 35 U.S.C. § 102(f) impact the case?
35 U.S.C. § 102(f) says that the patent must accurately list the inventors. If an inventor is left off or incorrectly named, the patent could be invalid, unless corrected. Iolab argued that since Dr. Link made a significant contribution to the lens design, the patent was invalid due to misjoinder (failure to name him), and the issue needed to be corrected under 35 U.S.C. § 256.
2. What did the Court of Appeals say about the error in naming inventors?
The Court agreed that if an inventor is omitted or wrongly named, the patent can still be corrected under 35 U.S.C. § 256 as long as the error wasn’t made with deceptive intent. The Court decided that, instead of deciding the issue itself, it should have been up to the jury to decide whether Dr. Link’s contribution was significant enough to make him a co-inventor.
3. How does 35 U.S.C. § 256 work in this case?
35 U.S.C. § 256 allows for correcting inventorship errors, as long as the mistake was made without deceptive intent. The Court explained that if the jury found Dr. Link was indeed a co-inventor, the patent could be corrected under this section, and the patent would not be invalidated. The patentee (Dr. Pannu) must have the opportunity to correct the inventorship if the jury rules in Iolab’s favor.
4. What was the court’s response to Iolab’s contention that Dr. Link was the sole inventor?
Iolab claimed that Dr. Link was the sole inventor because they argued that Dr. Pannu had already disclosed the idea of a one-piece lens in prior art. However, the Court rejected this argument. Even though Dr. Pannu had previously shared similar ideas, the Court emphasized that the collaboration between Dr. Pannu and Dr. Link was essential to the final invention. Dr. Pannu contributed significant ideas, and together they developed the full concept. So, Dr. Link couldn’t be the sole inventor, and Dr. Pannu was at least a co-inventor.
5. On whom does the burden of proof lie in proving incorrect inventorship?
The Court clarified that the burden of proof lies with the party challenging inventorship (in this case, Iolab). Iolab had to prove, by clear and convincing evidence, that Dr. Link should be listed as a co-inventor. The Court also ruled that Dr. Pannu (the patentee) should have been given the opportunity to correct the inventorship, based on the findings of the jury.
6. What was the best mode requirement in this case?
The Court acknowledged that if inventorship was corrected to include Dr. Link, Iolab could raise the issue of the best mode of practicing the invention. 35 U.S.C. § 112 requires the inventor to disclose the best way to make the invention known at the time of filing the patent. If Dr. Link was added as an inventor, Iolab could reassert its claim that the patent was invalid for failure to disclose the best mode, as the jury’s finding on that issue was based on Dr. Pannu being the sole inventor.
7. What did the Court ultimately decide regarding inventorship and non-joinder?
The Court found that the district court erred in granting JMOL (Judgment as a Matter of Law) without allowing the jury to decide whether Dr. Link was a co-inventor. The Court concluded that there was sufficient evidence for the jury to find that Dr. Link made a significant contribution to the invention. On remand, the jury should determine whether Dr. Link should be recognized as a co-inventor. If the jury agrees, Dr. Pannu would have the chance to correct the inventorship under 35 U.S.C. § 256.
8. What is Iolab’s argument regarding the district court’s claim construction of the term “substantially coplanar”?
Iolab argued that the term “substantially coplanar” should be interpreted to mean “non-vaulted” lenses, specifically referring to flat lenses. They contended that no other interpretation was supported by the patent specification or prosecution history. However, the Court disagreed, emphasizing that the term “substantially” in “substantially coplanar” allows for some variation in the angle, which was not limited to flat lenses. The district court correctly interpreted the term based on the specification, which indicates that the lens and the rings can lie in different planes, as long as they are close enough to each other.
9. How did the Court address Iolab’s argument about the snag-resistant means in the patent?
Iolab argued that the “snag-resistant means” should prevent any and all damage to the eye during insertion. However, the Court disagreed with this interpretation, pointing out that the claim only requires a snag-resistant means for smoothly guiding the lens. The Court emphasized that the patent did not claim damage prevention but rather focused on the functionality of smoothly guiding the lens across eye tissue, which is the purpose of the snag-resistant feature.
10. What was Iolab’s argument regarding the proof of infringement?
Iolab argued that even if the district court’s claim construction was correct, Pannu failed to prove that the accused products infringed the claims. Iolab contended that no reasonable jury could have found infringement because Pannu did not show that the accused lenses were “less likely to snag” compared to lenses that did not have the claimed snag-resistant means. However, Pannu responded by presenting substantial evidence, including showing that the accused lenses had smooth, rounded edges that functioned to smoothly guide and position the lens. Since Iolab did not offer any rebuttal or alternative explanation, the Court upheld the jury’s decision to reject Iolab’s motion for JMOL (Judgment as a Matter of Law) of non-infringement.
11. What did Pannu argue about the jury’s verdict on infringement and non-infringement?
Pannu challenged the jury’s verdict that two of the accused lenses infringed the patent. He argued that the district court abused its discretion by denying his request for a new trial, citing that the jury misunderstood how to measure the angle of the rings and supporting elements. However, the Court disagreed, ruling that Pannu’s argument was an attempt to reargue the case on appeal. The jury’s decision was based on conflicting evidence, and the Court found no error in the jury’s determination. Specifically, the jury found that one of the accused lenses did not meet the coplanar limitation, which was consistent with the evidence presented.
12. How did the Court address the procedural rulings and other arguments from both parties?
The Court found that the district court’s procedural rulings were within its discretion and did not constitute an abuse of discretion. The jury’s verdict was not against the great weight of the evidence, and its findings on infringement and non-infringement were amply supported by the evidence presented at trial. The Court concluded that Iolab and Pannu’s remaining arguments were unpersuasive.
13. What was the Court’s final decision regarding the inventorship issue and its impact on the patent? Did the jury decide to add Dr. Link’s name as a co-inventor?
The jury did not decide to add Dr. Link’s name as a co-inventor. While the Court of Appeals upheld the district court’s claim construction and the denial of post-trial motions challenging the infringement verdict, it found that the district court erred in granting JMOL regarding inventorship. The Court determined that Iolab presented sufficient evidence that could have convinced a reasonable jury that Dr. Link was a co-inventor. If the jury agrees with this finding and inventorship is not corrected, the patent could be invalidated under 35 U.S.C. § 102(f). Therefore, the Court vacated the judgment in favor of Dr. Pannu and remanded the case for a determination of the inventorship issue and any related matters.
What are Pannu Factors?
The Court in Pannu laid out three essential criteria for joint inventorship:
- Contributing to the Conception of the Invention – Merely following instructions or executing technical work isn’t enough; the person must have contributed to the inventive concept.
- Collaboration or Joint Effort – The contribution must be part of a cooperative effort rather than an independent discovery.
- Not an Insignificant Contribution – A minor or routine contribution doesn’t qualify as inventorship; it has to be meaningful.
Applicant of Pannu Factors in India
India’s Patents Act, 1970, recognizes joint inventorship, but it doesn’t provide a clear test for determining who qualifies as an inventor. In fields like pharmaceuticals, biotechnology, and software development, disputes over inventorship are common, particularly in collaborative projects. Some individuals may claim inventorship despite making only minor contributions. This is where the Pannu factors can serve as a useful framework.
For instance, in the development of a new drug, multiple researchers may contribute at different stages. However, should everyone involved be credited as an inventor? The Pannu factors help answer this by assessing:
- Contribution to Conception: Did the individual contribute to the original idea or the inventive concept?
- Non-Insignificant Contribution: Was their input substantial and not just a routine or administrative task?
- Beyond Well-Known Concepts: Did they provide insights that went beyond common knowledge or mere experimentation?
By applying this structured approach, Indian courts and patent offices can make more informed decisions about who truly qualifies as an inventor, preventing unjust claims while ensuring genuine contributors receive due credit.
AI and Inventorship in India
AI is rapidly transforming innovation, but its role in inventorship remains a legal gray area. Can an AI system be named as an inventor on a patent? Currently, Indian patent law does not allow it. Sections 2(1)(y) and 6 of the Patents Act, 1970, define an inventor as a “person”, implying that inventorship requires human agency.
A recent example is the DABUS case, where Dr. Stephen Thaler filed a patent application listing his AI system, DABUS, as the inventor. This application was challenged in multiple jurisdictions, including India, on the basis that AI lacks legal personhood and cannot claim rights over an invention. Opponents argued that India’s patent system is designed to reward human ingenuity, and recognizing AI as an inventor would require a legislative change.
However, AI is increasingly being used as a creative tool in R&D. This raises an important question: When AI is involved, how do we determine the human’s role in inventorship? The Pannu factors can help evaluate this by asking:
- Who initiated the idea? Did the human researcher provide the original concept or simply let AI generate solutions?
- Was the human’s role more than just pressing a button? Did they apply critical thinking and decision-making?
- Did the human contribute insights beyond just using AI as a standard tool?
By using these criteria, patent offices can distinguish between cases where a human truly contributed to an invention versus cases where AI was the primary creator.
Conclusion
As innovation advances, clear and objective criteria for determining inventorship are crucial to ensure rightful recognition. The Pannu factors offer a structured approach that Indian courts and patent offices can use to assess inventorship disputes, particularly in collaborative research and AI-assisted innovations. While India’s patent law currently mandates human inventors, the growing role of AI in the creative process signals the need for future legal and policy discussions to adapt to evolving technological realities.
Governing Law
35 U.S.C. § 102(f) | 35 U.S.C. § 256 | 35 U.S.C. § 112 | Patents Act, 1970: Sections 2(1)(y) and 6 | Pannu v. Iolab Corp., 155 F.3d 1344 (Fed. Cir. 1998)
